前列腺癌放疗后局部挽救治疗的系统综述与荟萃分析(MASTER)
该系统综述与荟萃分析纳入150项研究,比较放疗后局部复发前列腺癌的挽救性根治性前列腺切除(RP)、高强度聚焦超声(HIFU)、冷冻治疗、立体定向体部放疗(SBRT)、低剂量率(LDR)及高剂量率(HDR)近距离治疗的效果与毒性。调整后5年无复发生存率各 modality 间无显著差异,但SBRT、HDR及LDR近距离治疗的严重泌尿生殖道毒性显著低于RP,HDR近距离治疗的严重胃肠道毒性也显著低于RP。
要点
- 各挽救治疗 modality 调整后5年无复发生存率与RP相比无显著差异。
- SBRT、HDR及LDR近距离治疗的严重泌尿生殖道毒性显著低于RP。
- HDR近距离治疗的严重胃肠道毒性显著低于RP。
核心结论
- 各挽救治疗 modality 与RP相比,5年结局未发现大的差异。
- SBRT、HDR或LDR近距离再照射的严重泌尿生殖道毒性低于RP,HDR近距离再照射的严重胃肠道毒性低于RP。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE和MEDLINE,共纳入150项研究。
- 提取2年和5年无复发生存率及严重泌尿生殖道和胃肠道毒性的粗发生率作为终点。
- 采用随机效应荟萃分析汇总效应量并量化异质性,使用混合效应回归模型调整研究水平协变量后比较各 modality 与RP。
主要发现
- 调整后5年无复发生存率从冷冻治疗的50%到HDR近距离治疗和SBRT的60%,各 modality 与RP相比无显著差异。
- 严重泌尿生殖道毒性调整后发生率:RP为20%,SBRT为5.6%,HDR近距离治疗为9.6%,LDR近距离治疗为9.1%,三者均显著低于RP(p ≤ 0.001)。
- 严重胃肠道毒性调整后发生率:HDR近距离治疗为0.0%,RP为1.8%,HDR显著低于RP(p < 0.01),其他 modality 间未发现差异。
关键数值与推荐
- 调整后5年无复发生存率:冷冻治疗50%,HDR近距离治疗和SBRT均为60%,各 modality 与RP比较无显著差异。
- 严重泌尿生殖道毒性调整后发生率:RP 20%,SBRT 5.6%,HDR近距离治疗9.6%,LDR近距离治疗9.1%,再照射均显著低于RP(p ≤ 0.001)。
- 严重胃肠道毒性调整后发生率:HDR近距离治疗0.0% vs RP 1.8%(p < 0.01)。
临床怎么用
- 对于放疗后局部复发的前列腺癌,SBRT、HDR或LDR近距离再照射可作为RP的替代选择,以降低严重泌尿生殖道毒性。
- HDR近距离再照射可能降低严重胃肠道毒性,可与RP权衡。
- 各 modality 的5年无复发生存率与RP相当,选择时应结合毒性谱和患者个体情况。
局限性
- 各 modality 内研究间存在显著异质性,且协变量在不同 modality 间存在差异,需进行调整。
- 证据来源于研究水平荟萃分析,非个体患者数据。
- 需要前瞻性研究验证放疗后局部挽救治疗的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Management of locally recurrent prostate cancer after definitive radiotherapy remains controversial due to the perceived high rates of severe genitourinary (GU) and gastrointestinal (GI) toxicity associated with any local salvage modality. OBJECTIVE: To quantitatively compare the efficacy and toxicity of salvage radical prostatectomy (RP), high-intensity focused ultrasound (HIFU), cryotherapy, stereotactic body radiotherapy (SBRT), low-dose-rate (LDR) brachytherapy, and high-dose-rate (HDR) brachytherapy. EVIDENCE ACQUISITION: We performed a systematic review of PubMed, EMBASE, and MEDLINE. Two- and 5-yr recurrence-free survival (RFS) rates and crude incidences of severe GU and GI toxicity were extracted as endpoints of interest. Random-effect meta-analyses were conducted to characterize summary effect sizes and quantify heterogeneity. Estimates for each modality were then compared with RP after adjusting for individual study-level covariates using mixed-effect regression models, while allowing for differences in between-study variance across treatment modalities. EVIDENCE SYNTHESIS: A total of 150 studies were included for analysis. There was significant heterogeneity between studies within each modality, and covariates differed between modalities, necessitating adjustment. Adjusted 5-yr RFS ranged from 50% after cryotherapy to 60% after HDR brachytherapy and SBRT, with no significant differences between any modality and RP. Severe GU toxicity was significantly lower with all three forms of radiotherapeutic salvage than with RP (adjusted rates of 20% after RP vs 5.6%, 9.6%, and 9.1% after SBRT, HDR brachytherapy, and LDR brachytherapy, respectively; p ≤ 0.001 for all). Severe GI toxicity was significantly lower with HDR salvage than with RP (adjusted rates 1.8% vs 0.0%, p < 0.01), with no other differences identified. CONCLUSIONS: Large differences in 5-yr outcomes were not uncovered when comparing all salvage treatment modalities against RP. Reirradiation with SBRT, HDR brachytherapy, or LDR brachytherapy appears to result in less severe GU toxicity than RP, and reirradiation with HDR brachytherapy yields less severe GI toxicity than RP. Prospective studies of local salvage for radiorecurrent disease are warranted. PATIENT SUMMARY: In a large study-level meta-analysis, we looked at treatment outcomes and toxicity for men treated with a number of salvage treatments for radiorecurrent prostate cancer. We conclude that relapse-free survival at 5 years is equivalent among salvage modalities, but reirradiation may lead to lower toxicity.
引用
- Valle LF, Lehrer EJ, Markovic D, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2020. PMID: 33309278. doi:10.1016/j.eururo.2020.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。